Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Neuropharmacology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1441755

Rational analysis of data from LC-MS/MS: New insights in acylcarnitines as biomarkers for brain disorders or neurotoxicity

Provisionally accepted
Li Chen Li Chen *Ruiqin Zhu Ruiqin Zhu *Yaxing Ma Yaxing Ma *Chuixiu Huang Chuixiu Huang *Xiantao Shen Xiantao Shen *
  • Huazhong University of Science and Technology, Wuhan, China

The final, formatted version of the article will be published soon.

    Objective LC-MS/MS-based metabolomics is an important tool for studying diseaserelated biomarkers. Conventionally, different strategies have been used to screen biomarkers. However, many studies for biomarker screening by different strategies have ignored the dose-response relationship between the biomarker level and exposure level, and no relevant studies have described and compared different strategies in detail. Phenobarbital (PHB) which belongs to the barbiturates, was selected as the typical representative of neurotoxins. Acylcarnitines have been promising candidates for diagnostic biomarkers for several neurological disorders and neurotoxicity. In this work, we aimed to use an acute PHB poisoning animal model to clarify PHB poisoning effects on plasma & brain acylcarnitine changes and how to rationally analyze data from LC-MS/MS. Methods The acylcarnitine profiles in plasma and brain regions in an actuate PHB poisoning animal model were utilized. The dose-response relationship between plasma PHB and carnitine and acylcarnitines (CARs) in plasma and brain were assessed by the variance analysis trend test and Spearman's rank correlation test. In different strategies, principal component analysis (PCA) and partial least squares discriminant analysis (OPLS-DA) screened the differential CARs, variable importance plots (VIPs) were utilized to select putative biomarkers for PHB-induced toxicity, and receiver operating characteristic (ROC) curve analysis then illustrated the reliability of biomarkers.Results Under the first strategy, 14 potential toxicity biomarkers were obtained including 8 downregulated CARs with AUC > 0.8. Under the second strategy, 11 potential toxicity biomarkers were obtained containing 5 downregulated CARs with AUC > 0.8. Only when the dose-response relationship was fully considered, different strategies screen for the same biomarkers (plasma acetyl-carnitine (C2) and plasma decanoyl-carnitine (C10)), which indicated plasma acylcarnitines might serve as toxicity biomarkers. In addition, the plasma CAR level changes showed differences from brain CAR level changes, and correlations between plasma CARs and their brain counterparts were weak.We found that plasma C2 and C10 might serve as toxicity biomarkers for PHB poisoning disorders, and PHB poisoning effects on changes in plasma CARs may not be fully representative of changes in brain CARs.

    Keywords: Phenobarbital poisoning, Biomarker screening, data analysis, acylcarnitines, Two strategies

    Received: 31 May 2024; Accepted: 05 Aug 2024.

    Copyright: © 2024 Chen, Zhu, Ma, Huang and Shen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Li Chen, Huazhong University of Science and Technology, Wuhan, China
    Ruiqin Zhu, Huazhong University of Science and Technology, Wuhan, China
    Yaxing Ma, Huazhong University of Science and Technology, Wuhan, China
    Chuixiu Huang, Huazhong University of Science and Technology, Wuhan, China
    Xiantao Shen, Huazhong University of Science and Technology, Wuhan, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.